A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy
Introduction Treatment‐emergent small cell/neuroendocrine prostate cancer occurs predominantly in advanced or metastatic castration‐resistant prostate cancer that arises when prostate adenocarcinoma is transformed after androgen deprivation therapy. The clinical course for the pathogenesis involved...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12501 |
| _version_ | 1811333381929041920 |
|---|---|
| author | Taku Naiki Aya Naiki‐Ito Tatsuya Kawai Hirokazu Komatsu Ryutaro Nishikawa Masakazu Gonda Maria Aoki Yosuke Sugiyama Yoshihiko Tasaki Takahiro Yasui |
| author_facet | Taku Naiki Aya Naiki‐Ito Tatsuya Kawai Hirokazu Komatsu Ryutaro Nishikawa Masakazu Gonda Maria Aoki Yosuke Sugiyama Yoshihiko Tasaki Takahiro Yasui |
| author_sort | Taku Naiki |
| collection | DOAJ |
| description | Introduction Treatment‐emergent small cell/neuroendocrine prostate cancer occurs predominantly in advanced or metastatic castration‐resistant prostate cancer that arises when prostate adenocarcinoma is transformed after androgen deprivation therapy. The clinical course for the pathogenesis involved or associated genetic information have not been clearly elucidated. Case presentation A Japanese male, 63‐year‐old, underwent a para‐aortic lymph biopsy due to sudden severe bilateral leg edema, with a final diagnosis of stage IV prostate adenocarcinoma. He was initially responsive to upfront abiraterone with androgen deprivation therapy; however, relapse occurred in the liver and bone 10 months after initial treatment, with serum neuron‐specific enolase elevation and without prostate‐specific antigen elevation. Pathological findings of liver tumor revealed treatment‐emergent small cell/neuroendocrine prostate cancer. FoundationOne® CDx was used for cancer‐related gene profiling of liver tumor specimen; a BRCA2 mutation was identified. Conclusion Early detection of this transformation and pathological diagnosis can improve patient survival when genetic mutations, including BRCA 1/2. |
| first_indexed | 2024-04-13T16:51:51Z |
| format | Article |
| id | doaj.art-29643416f7f84b1681fb43dbc80196d3 |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-04-13T16:51:51Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-29643416f7f84b1681fb43dbc80196d32022-12-22T02:38:55ZengWileyIJU Case Reports2577-171X2022-11-015643143510.1002/iju5.12501A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsyTaku Naiki0Aya Naiki‐Ito1Tatsuya Kawai2Hirokazu Komatsu3Ryutaro Nishikawa4Masakazu Gonda5Maria Aoki6Yosuke Sugiyama7Yoshihiko Tasaki8Takahiro Yasui9Department of Nephro‐urology Nagoya City University, Graduate School of Medical Sciences Nagoya JapanDepartment of Experimental Pathology and Tumor Biology Nagoya City University, Graduate School of Medical Sciences Nagoya JapanDepartment of Radiology Nagoya City University, Graduate School of Medical Sciences Nagoya JapanDepartment of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya JapanDepartment of Obstetrics and Gynecology Nagoya City University Graduate School of Medical Sciences Nagoya JapanDepartment of Nephro‐urology Nagoya City University, Graduate School of Medical Sciences Nagoya JapanDepartment of Nephro‐urology Nagoya City University, Graduate School of Medical Sciences Nagoya JapanDepartment of Pharmacy Nagoya City University Hospital Nagoya JapanDepartment of Pharmacy Nagoya City University Hospital Nagoya JapanDepartment of Nephro‐urology Nagoya City University, Graduate School of Medical Sciences Nagoya JapanIntroduction Treatment‐emergent small cell/neuroendocrine prostate cancer occurs predominantly in advanced or metastatic castration‐resistant prostate cancer that arises when prostate adenocarcinoma is transformed after androgen deprivation therapy. The clinical course for the pathogenesis involved or associated genetic information have not been clearly elucidated. Case presentation A Japanese male, 63‐year‐old, underwent a para‐aortic lymph biopsy due to sudden severe bilateral leg edema, with a final diagnosis of stage IV prostate adenocarcinoma. He was initially responsive to upfront abiraterone with androgen deprivation therapy; however, relapse occurred in the liver and bone 10 months after initial treatment, with serum neuron‐specific enolase elevation and without prostate‐specific antigen elevation. Pathological findings of liver tumor revealed treatment‐emergent small cell/neuroendocrine prostate cancer. FoundationOne® CDx was used for cancer‐related gene profiling of liver tumor specimen; a BRCA2 mutation was identified. Conclusion Early detection of this transformation and pathological diagnosis can improve patient survival when genetic mutations, including BRCA 1/2.https://doi.org/10.1002/iju5.12501BRCA2 mutationcastration resistanttreatment‐emergent small cell/neuroendocrine prostate cancer |
| spellingShingle | Taku Naiki Aya Naiki‐Ito Tatsuya Kawai Hirokazu Komatsu Ryutaro Nishikawa Masakazu Gonda Maria Aoki Yosuke Sugiyama Yoshihiko Tasaki Takahiro Yasui A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy IJU Case Reports BRCA2 mutation castration resistant treatment‐emergent small cell/neuroendocrine prostate cancer |
| title | A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy |
| title_full | A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy |
| title_fullStr | A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy |
| title_full_unstemmed | A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy |
| title_short | A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy |
| title_sort | case of metastatic treatment emergent small cell neuroendocrine prostate cancer with brca2 mutation diagnosed by liver biopsy |
| topic | BRCA2 mutation castration resistant treatment‐emergent small cell/neuroendocrine prostate cancer |
| url | https://doi.org/10.1002/iju5.12501 |
| work_keys_str_mv | AT takunaiki acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT ayanaikiito acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT tatsuyakawai acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT hirokazukomatsu acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT ryutaronishikawa acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT masakazugonda acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT mariaaoki acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT yosukesugiyama acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT yoshihikotasaki acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT takahiroyasui acaseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT takunaiki caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT ayanaikiito caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT tatsuyakawai caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT hirokazukomatsu caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT ryutaronishikawa caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT masakazugonda caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT mariaaoki caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT yosukesugiyama caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT yoshihikotasaki caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy AT takahiroyasui caseofmetastatictreatmentemergentsmallcellneuroendocrineprostatecancerwithbrca2mutationdiagnosedbyliverbiopsy |